Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same

A composition comprising a polypeptide comprising an extracellular domain or fragment thereof of an ORP150 polypeptide expressed on the cell surface of a plasmacytoma cell, a multiple myeloma cell, a colorectal cancer cell, a gastric cancer cell, or an esophageal cancer cell, and a pharmaceutically acceptable carrier.

A method for treating cancer in an individual having cancer selected from the group consisting of plasmacytoma, multiple myeloma, colorectal cancer, gastric cancer, and esophageal cancer, comprising administering to the individual an effective amount of a polypeptide comprising an extracellular domain or fragment thereof of an ORP150 polypeptide expressed on the cell surface of a plasmacytoma cell, a multiple myeloma cell, a colorectal cancer cell, a gastric cancer cell, or an esophageal cancer cell.

A method for preventing or delaying the development of cancer in an individual having cancer selected from the group consisting of plasmacytoma, multiple myeloma, colorectal cancer, gastric cancer, and esophageal cancer or having an increased risk for cancer selected from the group consisting of plasmacytoma, multiple myeloma, colorectal cancer, gastric cancer, and esophageal cancer, comprising administering to the individual an effective amount of a polypeptide comprising an extracellular domain or fragment thereof of an ORP150 polypeptide expressed on the cell surface of a plasmacytoma cell, a multiple myeloma cell, a colorectal cancer cell, a gastric cancer cell, or an esophageal cancer cell.

A kit comprising a pharmaceutical composition comprising a polypeptide comprising an extracellular domain or fragment thereof of an ORP150 polypeptide expressed on the cell surface of a plasmacytoma cell, a multiple myeloma cell, a colorectal cancer cell, a gastric cancer cell, or an esophageal cancer cell, and instructions for administering an effective amount of the pharmaceutical composition to an individual for treating cancer selected from the group consisting of plasmacytoma, multiple myeloma, colorectal cancer, gastric cancer, and esophageal cancer.

A kit comprising a pharmaceutical composition comprising a polypeptide comprising an extracellular domain or fragment thereof of an ORP150 polypeptide expressed on the cell surface of a plasmacytoma cell, a multiple myeloma cell, a colorectal cancer cell, a gastric cancer cell, or an esophageal cancer cell, and instructions for administering an effective amount of the pharmaceutical composition to an individual for preventing or delaying the development of cancer selected from the group consisting of plasmacytoma, multiple myeloma, colorectal cancer, gastric cancer, and esophageal cancer.